Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jade Biosciences, Inc.JBIO · Entity 4757 | Director | June 25, 2026 | June 27, 2026 |
| KYNTRA BIO, INC.FGEN · Entity 7431 | EVP, Chief Medical Officer | September 06, 2023 | September 08, 2023 |
| Vir Biotechnology, Inc.VIR · Entity 4522 | EVP and Chief Medical Officer | February 24, 2026 | February 26, 2026 |
| Zura Bio LtdZURA · Entity 5413 | Director | June 17, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jade Biosciences, Inc.
Report date June 25, 2026 · Filed June 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.81 · Expires 2036-06-24 | Direct | 47,675 |
Reported balance
After 2026-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-25 · Grant · Acquired 47,675 · Balance 47,675 F1: 1/36th of the total number of shares of common stock subject to the option vest monthly following the date of grant, subject to the Reporting Person's continued service to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/36th of the total number of shares of common stock subject to the option vest monthly following the date of grant, subject to the Reporting Person's continued service to the Issuer through each vesting date.
KYNTRA BIO, INC.
Report date September 06, 2023 · Filed September 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 159,917 |
Reported balance
After 2023-09-06 transaction · row 1
1 source rowRow 1 · 2023-09-06 · Tax withholding · Disposed 1,860 · Balance 159,917 F1: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units.
Vir Biotechnology, Inc.
Report date February 24, 2026 · Filed February 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 154,024 |
Ending reported balance
After 2026-02-25 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-24 · Sale · Disposed 1,616 · Balance 155,913 F1: Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units. The sale does not represent a discretionary trade by the Reporting Person. Row 2 · 2026-02-25 · Sale · Disposed 1,889 · Balance 154,024 F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units. The sale does not represent a discretionary trade by the Reporting Person.
F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2025.
Zura Bio Ltd
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.62 · Expires 2036-06-17 | Direct | 51,000 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 51,000 · Balance 51,000 F1: This option vests in twelve substantially equal monthly installments over a one-year period measured from June 17, 2026; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests in twelve substantially equal monthly installments over a one-year period measured from June 17, 2026; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 25, 2026 Filed Jun 27, 2026 01:20 UTC | Jade Biosciences, Inc. JBIO · Entity 4757 | GrantStock Option (Right to Buy) · Derivative | 47,675 | $0.00 Strike: $21.81 | $0.00 |
DisclosureSEC source: 0001193125-26-286434 · ownership.xml · derivative · entry 1 Eisner Mark · CIK 0001834161 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,675 Underlying: Common Stock · 47,675 shares Expires 2036-06-24 F1 · derivative.exercise_date: 1/36th of the total number of shares of common stock subject to the option vest monthly following the date of grant, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:15 UTC | Zura Bio Ltd ZURA · Entity 5413 | GrantShare Option (Right to Buy) · Derivative | 51,000 | $0.00 Strike: $3.62 | $0.00 |
DisclosureSEC source: 0001834161-26-000008 · form4-06222026_040603.xml · derivative · entry 1 Eisner Mark · CIK 0001834161 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,000 Underlying: Class A Ordinary Shares · 51,000 shares Expires 2036-06-17 F1 · derivative.exercise_date: This option vests in twelve substantially equal monthly installments over a one-year period measured from June 17, 2026; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| February 25, 2026 Filed Feb 26, 2026 21:55 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,889 | $9.82 | $18,549.98 |
DisclosureSEC source: 0001628280-26-012394 · wk-form4_1772142916.xml · nonDerivative · entry 2 Eisner Mark · CIK 0001834161 · EVP and Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 154,024 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2025. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:55 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,616 | $9.53 | $15,404.68 |
DisclosureSEC source: 0001628280-26-012394 · wk-form4_1772142916.xml · nonDerivative · entry 1 Eisner Mark · CIK 0001834161 · EVP and Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 155,913 F1 · kind: Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 00:11 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 2,089 | $7.45 | $15,568.90 |
DisclosureSEC source: 0001628280-26-011329 · wk-form4_1771978287.xml · nonDerivative · entry 2 Eisner Mark · CIK 0001834161 · EVP and Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 157,529 F2 · kind: Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of RSUs. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 22, 2026 Filed Feb 25, 2026 00:11 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 110,000 | $0.00 Strike: $7.56 | $0.00 |
DisclosureSEC source: 0001628280-26-011329 · wk-form4_1771978287.xml · derivative · entry 3 Eisner Mark · CIK 0001834161 · EVP and Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2036-02-21 F3 · derivative.exercise_date: 25% of the shares subject to the stock option will vest and become exercisable on February 22, 2027, and the remaining shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| February 22, 2026 Filed Feb 25, 2026 00:11 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 55,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-011329 · wk-form4_1771978287.xml · nonDerivative · entry 1 Eisner Mark · CIK 0001834161 · EVP and Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 159,618 F1 · kind: Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan. Read SEC document |
| February 21, 2026 Filed Feb 25, 2026 02:14 UTC | Zura Bio Ltd ZURA · Entity 5413 | GrantShare Option (Right to Buy) · Derivative | 37,812 | $0.00 Strike: $6.53 | $0.00 |
DisclosureSEC source: 0001834161-26-000006 · form4-02252026_020259.xml · derivative · entry 1 Eisner Mark · CIK 0001834161 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,812 Underlying: Class A Ordinary Shares · 37,812 shares Expires 2036-02-21 F1 · derivative.exercise_date: This option vests in twelve substantially equal monthly installments over a one-year period measured from February 21, 2026; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| July 17, 2025 Filed Jul 17, 2025 22:46 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 3,586 | $5.47 | $19,629.05 |
DisclosureSEC source: 0001628280-25-035269 · wk-form4_1752792412.xml · nonDerivative · entry 2 Eisner Mark · CIK 0001834161 · EVP and Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,618 F2 · kind: Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 5, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.41 to $5.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| July 15, 2025 Filed Jul 17, 2025 22:46 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 6,796 | $5.47 | $37,161.89 |
DisclosureSEC source: 0001628280-25-035269 · wk-form4_1752792412.xml · nonDerivative · entry 1 Eisner Mark · CIK 0001834161 · EVP and Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 108,204 F1 · kind: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. Read SEC document |
| February 22, 2025 Filed Feb 25, 2025 20:39 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $9.57 | $0.00 |
DisclosureSEC source: 0001628280-25-007699 · wk-form4_1740515940.xml · derivative · entry 2 Eisner Mark · CIK 0001834161 · EVP and Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2035-02-21 F2 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on February 22, 2026, and the remainder vest in 36 equal monthly installments thereafter. Read SEC document |
| February 22, 2025 Filed Feb 25, 2025 20:39 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007699 · wk-form4_1740515940.xml · nonDerivative · entry 1 Eisner Mark · CIK 0001834161 · EVP and Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,000 F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan. Read SEC document |
| July 15, 2024 Filed Jul 16, 2024 20:40 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $9.37 | $0.00 |
DisclosureSEC source: 0000950170-24-083951 · ownership.xml · derivative · entry 2 Eisner Mark · CIK 0001834161 · EVP and Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2034-07-14 F2 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on July 15, 2025, and the remainder vest in 36 equal monthly installments thereafter. Read SEC document |
| July 15, 2024 Filed Jul 16, 2024 20:40 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-083951 · ownership.xml · nonDerivative · entry 1 Eisner Mark · CIK 0001834161 · EVP and Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan. Read SEC document |
| September 06, 2023 Filed Sep 8, 2023 20:59 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 1,860 | $0.96 | $1,791.37 |
DisclosureSEC source: 0001209191-23-048809 · doc4.xml · nonDerivative · entry 1 Eisner Mark · CIK 0001834161 · EVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 159,917 F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. Read SEC document |
| September 01, 2023 Filed Sep 7, 2023 00:55 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 1,085 | $1.06 | $1,150.10 |
DisclosureSEC source: 0001209191-23-048555 · doc4.xml · nonDerivative · entry 1 Eisner Mark · CIK 0001834161 · EVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,777 F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 23:12 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,042 | $17.04 | $34,791.60 |
DisclosureSEC source: 0001209191-23-036054 · doc4.xml · nonDerivative · entry 1 Eisner Mark · CIK 0001834161 · EVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,862 F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. Read SEC document |
| June 02, 2023 Filed Jun 5, 2023 20:22 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,090 | $18.83 | $20,524.70 |
DisclosureSEC source: 0001209191-23-034288 · doc4.xml · nonDerivative · entry 1 Eisner Mark · CIK 0001834161 · EVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,904 F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 20:32 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 9,182 | $18.78 | $172,472.85 |
DisclosureSEC source: 0001209191-23-023592 · doc4.xml · nonDerivative · entry 1 Eisner Mark · CIK 0001834161 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,994 F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. Read SEC document |
| March 10, 2023 Filed Mar 11, 2023 02:55 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 6,255 | $20.20 | $126,334.11 |
DisclosureSEC source: 0001209191-23-018063 · doc4.xml · nonDerivative · entry 5 Eisner Mark · CIK 0001834161 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,176 F5 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of PSU TSR previously reported in Table I. Read SEC document |
| March 10, 2023 Filed Mar 11, 2023 02:55 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 3,885 | $20.20 | $78,466.51 |
DisclosureSEC source: 0001209191-23-018063 · doc4.xml · nonDerivative · entry 4 Eisner Mark · CIK 0001834161 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,431 F4 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of PSU Milestone previously reported in Table I. Read SEC document |
| March 08, 2023 Filed Mar 11, 2023 02:55 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 12,451 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-018063 · doc4.xml · nonDerivative · entry 3 Eisner Mark · CIK 0001834161 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,316 F3 · shares: Represents the number of shares released for PSU TSR Grant vested on March 8, 2023. Read SEC document |
| March 08, 2023 Filed Mar 11, 2023 02:55 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 7,732 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-018063 · doc4.xml · nonDerivative · entry 2 Eisner Mark · CIK 0001834161 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,865 F2 · shares: Represents the number of shares released for PSU Milestone Grant vested on March 8, 2023. Read SEC document |
| March 08, 2023 Filed Mar 11, 2023 02:55 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 7,363 | $21.16 | $155,770.89 |
DisclosureSEC source: 0001209191-23-018063 · doc4.xml · nonDerivative · entry 1 Eisner Mark · CIK 0001834161 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,133 F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 21:59 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,187 | $21.87 | $25,959.69 |
DisclosureSEC source: 0001209191-23-016362 · doc4.xml · nonDerivative · entry 1 Eisner Mark · CIK 0001834161 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,496 F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. Read SEC document |
| February 21, 2023 Filed Feb 24, 2023 01:38 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $22.60 | $0.00 |
DisclosureSEC source: 0001209191-23-012425 · doc4.xml · derivative · entry 2 Eisner Mark · CIK 0001834161 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2033-02-20 F2 · derivative.exercise_date: Twenty-five percent of the shares subject to the option will vest on March 1, 2024, and the remainder of the options will vest in equal amounts quarterly thereafter for the following three years. Read SEC document |
| February 21, 2023 Filed Feb 24, 2023 01:38 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 32,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-012425 · doc4.xml · nonDerivative · entry 1 Eisner Mark · CIK 0001834161 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,683 F1 · shares: Represents the grant of restricted stock units (RSUs). Twenty-five percent of the RSUs will vest on March 6, 2024, and the remainder of the RSUs will vest in equal amounts quarterly thereafter for the following three years. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 22:41 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 1,084 | $15.04 | $16,303.36 |
DisclosureSEC source: 0001209191-22-059472 · doc4.xml · nonDerivative · entry 1 Eisner Mark · CIK 0001834161 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,183 F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 21:21 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 6,777 | $13.01 | $88,168.77 |
DisclosureSEC source: 0001209191-22-052381 · doc4.xml · nonDerivative · entry 1 Eisner Mark · CIK 0001834161 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,267 F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. Read SEC document |
| September 01, 2022 Filed Sep 2, 2022 21:30 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 756 | $13.09 | $9,896.04 |
DisclosureSEC source: 0001209191-22-048555 · doc4.xml · nonDerivative · entry 1 Eisner Mark · CIK 0001834161 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,044 F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:21 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 1,141 | $9.61 | $10,965.01 |
DisclosureSEC source: 0001209191-22-034041 · doc4.xml · nonDerivative · entry 1 Eisner Mark · CIK 0001834161 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,800 F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 23:28 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 6,442 | $12.02 | $77,432.84 |
DisclosureSEC source: 0001209191-22-022095 · doc4.xml · nonDerivative · entry 1 Eisner Mark · CIK 0001834161 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,941 F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:04 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 756 | $13.62 | $10,296.72 |
DisclosureSEC source: 0001209191-22-015366 · doc4.xml · nonDerivative · entry 1 Eisner Mark · CIK 0001834161 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,383 F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 02:01 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $15.60 | $0.00 |
DisclosureSEC source: 0001209191-22-010452 · doc4.xml · derivative · entry 2 Eisner Mark · CIK 0001834161 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-02-13 F2 · derivative.exercise_date: Twenty-five percent of the shares subject to the option will vest on March 1, 2023, and the remainder of the options will vest in equal amounts quarterly thereafter for the following three years. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 02:01 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-010452 · doc4.xml · nonDerivative · entry 1 Eisner Mark · CIK 0001834161 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,139 F1 · shares: Represents the grant of restricted stock units (RSUs). Twenty-five percent of the RSUs will vest on March 6, 2023, and the remainder of the RSUs will vest in equal amounts quarterly thereafter for the following three years. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:44 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 7,043 | $14.82 | $104,377.26 |
DisclosureSEC source: 0001209191-22-001743 · doc4.xml · nonDerivative · entry 1 Eisner Mark · CIK 0001834161 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,139 F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 21:03 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 4,338 | $12.65 | $54,875.70 |
DisclosureSEC source: 0001209191-21-067780 · doc4.xml · nonDerivative · entry 1 Eisner Mark · CIK 0001834161 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,182 F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. Read SEC document |
| October 04, 2021 Filed Oct 6, 2021 23:25 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 44,520 | $0.00 Strike: $9.93 | $0.00 |
DisclosureSEC source: 0001209191-21-059869 · doc4.xml · derivative · entry 2 Eisner Mark · CIK 0001834161 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,520 Underlying: Common Stock · 44,520 shares Expires 2031-10-04 F2 · derivative.exercise_date: Fifty percent of the shares subject to the option vests on each September 30, 2022 and March 31, 2023. Read SEC document |
| October 04, 2021 Filed Oct 6, 2021 23:25 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 74,520 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-059869 · doc4.xml · nonDerivative · entry 1 Eisner Mark · CIK 0001834161 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,520 F1 · shares: Represents the grant of restricted stock units. Twenty-five percent of the restricted stock units vest on each December 31, 2021, March 31, 2022, September 30, 2022 and March 31, 2023. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 23:51 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $41.25 | $0.00 |
DisclosureSEC source: 0001209191-20-061651 · doc4.xml · derivative · entry 2 Eisner Mark · CIK 0001834161 · Incoming Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2030-12-01 F2 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vest on December 1, 2021 and the remainder vest in equal amounts quarterly thereafter for the following three years. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 23:51 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-061651 · doc4.xml · nonDerivative · entry 1 Eisner Mark · CIK 0001834161 · Incoming Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 F1 · shares: Represents the grant of restricted stock units. Twenty-five percent of the restricted stock units vest on December 1, 2021, and the remainder vest in equal amounts quarterly thereafter for the following three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.